Discover
Rheumatology & Arthritis Learning Network
Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA
Update: 2023-11-07
Share
Description
Dr Fleischmann reviews a post hoc analysis of the SELECT phase 3 trial of upadacitinib in rheumatoid arthritis and the safety of JAK inhibitors among RA patients at risk for cardiovascular events.
Comments
In Channel





















